Suan-Zao-Ren decoction for insomnia
A protocol for a systematic review and meta-analysis

Zhijian Song, MMab, Ping Fan, MMA, Qi Zhang, MMab, Yang Yang, MMab, Qinan Zhan, MMb, Xueyu Liu, MMc, Yurong Xiong, MMb

Abstract
Background: Chinese herbal medicine has been widely used to relieve insomnia. Among them, Suan-Zao-Ren decoction (SZRD) has a significant effect in alleviating insomnia. The purpose of this systematic review is to evaluate the effectiveness and safety of SZRD in treating insomnia.

Methods: Relevant randomized controlled trials (RCTs) will be searched from the databases of Embase, PubMed, the Cochrane Library, the China National Knowledge Infrastructure, Wanfang Database and Chinese Science and Technology Periodical Database from their inception to July 2020. Two independent reviewers will select studies, collect data, and assess the methodology quality by the Cochrane risk of bias tool. Statistical analysis is processed by RevMan V.5.3 software.

Results: The results of this systematic review will provide an assessment of SZRD treatment of insomnia, and aims to prove the effectiveness and safety of SZRD.

Conclusion: This study will provide a credible Evidence-based for the treatment of Insomnia with SZRD.

Abbreviations: 95%CI = 95% confidence interval, MD = mean differences, RCTs = randomized controlled trials, ROB = risk of bias, RR = relative risk, SZRD = Suan-Zao-Ren decoction.

Keywords: insomnia, protocol, Suan Zao Ren decoction, systematic review

1. Introduction
Insomnia is a common public health problem, affecting about 40% to 50% of the general population, and its prevalence is increasing. In the United States, it is estimated that one-third of adults are experiencing insomnia. Long-term insomnia seriously affects the quality of life of patients. At the same time, insomnia increases the risk of many health problems, such as cardiovascular disease, hypertension, myocardial infarction chronic heart failure and depression, etc. In addition, insomnia also leads to a decline in work performance. In the United States, the estimated annual economic loss due to insomnia is more than $63 billion. Therefore, insomnia puts a heavy burden on individuals and society.

As far as the treatment of insomnia is concerned, pharmacotherapy is a common method and recommended by clinical guidelines. Although the short-term efficacy of pharmacotherapy is obvious, its long-term clinical application is limited by side effects, including dependence, dizziness and gastrointestinal reactions. Therefore, it is necessary to explore more safe and effective alternative therapies to treat insomnia. Chinese Herbal Medicine (CHM) is one of the most popular alternative treatments. Recent systematic review supports the use of CHM as a whole for insomnia.

Suan-Zao-Ren decoction (SZRD) is a well-known formula, which is composed of five herbs, namely Ziziphi Spinosae Semen (ZSS), Poria (P), Chuanxiong Rhizoma (CR), Anemarrhenae Rhizoma (AR), and Glycyrrhizae Radix Et Rhizoma (GRR). As a representative drug, SZRD has been widely used to treat insomnia and anxiety disorders for thousands of years. Modern pharmacological studies have shown that SZRD has anticonvulsant, nourish blood, protect cardiovascular system and enhance immunity. Therefore, in modern clinical treatment, SZRD is considered to be a safe, effective, hygienic, convenient, and inexpensive supplemental alternative treatment method.

Although the benefits of SZRD in the treatment of insomnia have been widely reported, the effectiveness of SZRD has not been systematically and scientifically evaluated. This study uses the method of evidence-based medicine to analyze and evaluate...
the RCTs of patients with Insomnia treated by SZRD to clarify the safety and effectiveness of SZRD for insomnia.

2. Methods

The protocol of this study has been registered with the Open Science Framework (OSF, https://osf.io/). The registration DOI of this review is 10.17605/OSF.IO/4P6K8. We will refer to the preferred reporting items for the systematic review and meta-analysis (PRISMA) to perform this study.

2.1. Inclusion criteria for study selection

2.1.1. Types of studies. RCTs assessing SZRD treatment for Insomnia will be eligible for inclusion. No language and publication status restrictions.

2.1.2. Types of participants. Insomnia patients with definite diagnosis will be included in this systematic review. There are no restrictions on race, age, gender, or nationality.

2.1.3. Types of interventions

2.1.3.1. Experimental interventions. Using SZRD or modified SZRD as the experimental intervention, regardless of the administration type, dose, or intervention duration.

2.1.3.2. Control interventions. The control group will receive one of the following treatment methods: pharmacotherapy, Cognitive-Behavioral Therapy (CBT) or placebo.

2.1.4. Types of outcome measures

2.1.4.1. Primary outcome. Pittsburgh sleep quality index (PSQI) and Clinical efficacy will be accepted as the primary outcomes.

2.1.4.2. Additional outcomes. The safety assessment will be regarded as an additional result.

2.2. Search methods for the identification of studies

The following databases will be searched: PubMed, Embase, Cochrane Library, the China National Knowledge Infrastructure, Chinese Science and Technology Periodical Database and Wanfang Database. We will search the databases from the beginning to July 2020. Search terms consist of disease (insomnia OR sleep OR sleepless) and intervention (Suan-Zao-Ren decoction OR Suan-Zao-Ren Tang OR Suan Zao Ren OR SuanZaoRen) and research types (randomized controlled trial, controlled clinical trial, random trials). The PubMed search strategy is shown in Table 1.

2.3. Data collection and analysis

2.3.1. Selection of studies. We will import the data retrieved from the relevant database into EndNote X8 software. After that, two independent authors will read the title, abstract and full text of the literature according to the inclusion criteria to assess the eligibility of these articles. If there are any disagreements, the 2 authors will discuss and reach an agreement. The study selection procedure is summarized in Figure 1.

2.3.2. Data extraction and management. Two authors will independently extract relevant data from the eligible RCTs, including author, participant characteristics, sample size, intervention details, follow-up, outcomes, and adverse events. The above information will be cross-checked by two authors. If necessary, we will also contact the corresponding author for more information.

2.4. Risk of bias assessment

We will evaluate the risk of bias from 7 items based on the Cochrane Collaboration’s tool. The contents include: random sequence generation, allocation concealment, the blinding method for patients, researchers and outcomes assessors, incomplete result data, selective reports and other sources of bias. Each item will be rated as high, low or unclear risk of bias.[21] The assessment will be completed by two authors independently, and all disagreements will be resolved through discussion.

2.5. Quantitative data synthesis and statistical methods

2.5.1. Quantitative data synthesis. RevMan 5.3 software will be used for statistical analysis. Continuous results will be calculated as mean difference (MD) and 95% CI. Dichotomous outcomes will be calculated with the risk ratio (RR) and 95% CI.

2.5.2. Assessment of heterogeneity. Heterogeneity will be evaluated by I² test and Chi-square test. When I² ≤ 50% and P > .10, the research result will be regarded as homogeneous; otherwise, it will be considered as heterogeneous.

2.5.3. Assessment of reporting biases. We will examine the publication bias by evaluating the symmetry of the funnel plot. If the funnel plot is not symmetric, the results of the study may have a publication bias.

2.5.4. Subgroup analysis. If there is significant heterogeneity in our study, we will perform a subgroup analysis based on the type of control group.

2.5.5. Sensitivity analysis. If enough RCTs are included in our study, we will conduct sensitivity analysis based on study quality, sample size, and missing data to assess the robustness of the meta-analysis.

2.5.6. Grading the quality of evidence. We will evaluate the quality of evidence by the Grading of Recommendations

Table 1

| Search strategy used in PubMed database. |
|-----------------------------------------|
| Number | Search Items                        |
|--------|-------------------------------------|
| 1      | insomnia, ti, ab                    |
| 2      | sleep, ti, ab                       |
| 3      | sleepless, ti, ab                   |
| 4      | 1 or 2–3                            |
| 5      | Suan-Zao-Ren decoction, ti, ab      |
| 6      | Suan-Zao-Ren Tang, ti, ab           |
| 7      | Suan Zao Ren, ti, ab                |
| 8      | SuanZaoRen, ti, ab                  |
| 9      | 5 or 6–8                            |
| 10     | randomized controlled trial, ti, ab |
| 11     | random trials, ti, ab               |
| 12     | controlled clinical trial, ti, ab   |
| 13     | 10 or 11–12                         |
| 14     | 4 and 9 and 13                       |
Assessment, Development and Evaluation and divide them into 4 levels: high, medium, low or very low.[22,23]

3. Discussion

Traditional Chinese medicine (TCM) has been widely used in the treatment of insomnia, with satisfactory therapeutic effects and fewer side effects. Among them, SZRD has always been popular for the treatment of insomnia and restless.[24] Although the benefits of SZRD for insomnia have been widely reported,[25,26] the effectiveness of SZRD has not been systematically and scientifically evaluated. The aim of this study is to evaluate the effectiveness and safety of SZRD for insomnia. The conclusion of this study may provide evidence-based medical advice for the treatment of insomnia by SZRD.

Author contributions

Data curation: Zhijian Song, Qi Zhang.
Formal analysis: Zhijian Song, Yang Yang.
Investigation: Xueyu Liu, Qinan Zhan.
Methodology: Yurong Xiong, Yang Yang.
Project administration: Zhijian Song, Ping Fan.
Software: Qi Zhang, Qinan Zhan.
Supervision: Ping Fan.
Validation: Ping Fan, Xueyu Liu.

Visualization: Qi Zhang, Xueyu Liu.
Writing – original draft: Zhijian Song, Ping Fan.
Writing – review & editing: Zhijian Song, Ping Fan.

References

[1] Birling Y, Jia M, Li G, et al. Zao Ren An Shen for insomnia: a systematic review with meta-analysis. Sleep Med 2020;69:41–50.
[2] Riemann D, Baglioni C, Bassetti C, et al. European guideline for the diagnosis and treatment of insomnia. J Sleep Res 2017;26:675–700.
[3] Roth T. Prevalence, associated risks, and treatment patterns of insomnia. J Clin Psychiatry 2005;66(Suppl 9):10–3. quiz 42–3.
[4] Li M, Zhang XW, Hou WS, et al. Insomnia and risk of cardiovascular disease: a meta-analysis of cohort studies. Int J Cardiol 2014;176:1044–7.
[5] Laugsand LE, Vatten LJ, Platou C, et al. Insomnia and the risk of acute myocardial infarction: a population study. Circulation 2011;124:2073–81.
[6] Baglioni C, Battagliese G, Feige B, et al. Insomnia as a predictor of depression: a meta-analytic evaluation of longitudinal epidemiological studies. J Affect Disord 2011;135:10–9.
[7] Kessler RC, Berglund PA, Coulouvrat C, et al. Insomnia and the performance of US workers: results from the America insomnia survey. Sleep 2011;34:1161–71.
[8] Kansagara D, Wilt TJ, Starkey M, et al. Management of chronic insomnia disorder in adults. Ann Intern Med 2016;165:892.
[9] Feng G, Han M, Li X, et al. Clinical effectiveness of Tui Na for insomnia compared with estazolam: A systematic review and meta-analysis of randomized controlled trials. Complement Ther Med 2019;47:102186.
[10] Qaseem A, Kansagara D, Forciea MA, et al. Management of chronic insomnia disorder in adults: a clinical practice guideline from the American college of physicians. Ann Intern Med 2016;165:125–33.

[11] Glass J, Lantex KL, Herrmann N, et al. Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits. BMJ 2003;331:1169.

[12] Lisczak SC, Rowlett JK. Abuse and dependence liability of benzodiazepine-type drugs: GABA(A) receptor modulation and beyond. Pharmacol Biochem Behav 2008;90:74–89.

[13] Pearson NJ, Johnson LL, Nahin RL. Insomnia, trouble sleeping, and complementary and alternative medicine: analysis of the 2002 national health interview survey data. Arch Intern Med 2006;166:1775–82.

[14] Lee KH, Tsai YT, Lai JN, et al. Concurrent use of hypnotic drugs and Chinese herbal medicine therapies among Taiwanese adults with insomnia symptoms: a population-based study. Evid Based Complement Alternat Med 2013;2013:987862.

[15] Ni X, Shergis JL, Guo X, et al. Updated clinical evidence of Chinese herbal medicine for insomnia: a systematic review and meta-analysis of randomized controlled trials. Sleep Med 2015;16:1462–81.

[16] Chen FP, Jong MS, Chen YC, et al. Prescriptions of Chinese herbal medicines for insomnia in Taiwan during 2002. Evid Based Complement Alternat Med 2011;2011:236341.

[17] Chen HC, Hsieh MT, Lai E. Studies on the suanzaoren tang in the treatment of anxiety. Psychopharmacology (Berl) 1985;85:486–7.

[18] Yi PL, Tsai CH, Chen YC, et al. Gamma-aminobutyric acid (GABA) receptor mediates suanzaoren tang, a traditional Chinese herb remedy, induced sleep alteration. J Biomed Sci 2007;14:285–97.

[19] Peng WH, Hsieh MT, Lee YS, et al. Anxiolytic effect of seed of Ziziphus jujuba in mouse models of anxiety. J Ethnopharmacol 2000;72:435–41.

[20] Du Y, He B, Li Q, et al. Simultaneous determination of multiple active components in rat plasma using ultra-fast liquid chromatography with tandem mass spectrometry and application to a comparative pharmacokinetic study after oral administration of Suan-Zao-Ren decoction and Suan-Zao-Ren granule. J Sep Sci 2017;40:2097–106.

[21] Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928.

[22] Guyatt GH, Oxman AD, Schunemann HJ, et al. GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. J Clin Epidemiol 2011;64:380–2.

[23] Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 2015;4:1.

[24] Du Y, Wu B, Xiao F, et al. Untargeted metabolomic study on the insomnia effect of Suan-Zao-Ren decoction in the rat serum and brain using ultra-high-performance liquid chromatography quadrupole time-of-flight mass spectrometry combined with data processing analysis. J Sep Sci 2020;43:2013–30.

[25] Chan YY, Chen YH, Yang SN, et al. Clinical Efficacy of Traditional Chinese Medicine, Suan Zao Ren Tang, for sleep disturbance during methadone maintenance: a randomized, double-blind, placebo-controlled trial. Evid Based Complement Alternat Med 2015;2015:710895.

[26] Yeh CH, Arnold CK, Chen YH, et al. Suan zao ren tang as an original treatment for sleep difficulty in climacteric women: a prospective clinical observation. Evid Based Complement Alternat Med 2011;2011:673813.